# Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

> **NCT00073528** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1286 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Letrozole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00073528
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12-09
- **Primary completion:** 2008-06-03
- **Final completion:** 2018-03-22
- **Target enrollment:** 1286 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073528, "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00073528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*